

# Synopsys, Inc. Class Action Lawsuit

U.S. Securities Litigation

**Synopsys, Inc. (NASDAQ: SNPS)**: Synopsys, Inc. has been sued for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. The decline in Synopsys' share price caused significant losses to investors. The class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Synopsys securities. The class action is pending in the U.S. District Court for the Northern District of California and is captioned *Kim v. Synopsys, Inc., et al.*, No. 3:25-cv-09410.

If you lost money on your investments in Synopsys, you are encouraged to submit your information.

### Why Was Synopsys Sued for Securities Fraud?

Synopsys provides design automation software products used to design and test integrated circuits. The Company's Design IP segment, which provides pre-designed silicon components to semiconductor companies, has been the Company's fastest-growing segment, growing from 25% of its revenue in 2022, to 31% in 2024.

During the relevant period, Synopsys told investors that its customers "rely on Synopsys IP to minimize integration risk and speed time to market" and that it was seeing "strength in Europe and South Korea." Synopsys also stated it was "continuing to develop and deploy[] AI into our products and the operations of our business."

As alleged, in truth, the Company's Design IP customers began to require additional customization for IP components, which was deteriorating the economics of its Design IP business and jeopardizing its business model.

## Why Did Synopsys' Stock Drop?

On September 9, 2025, Synopsys released its Q3 2025 financial results, revealing its "IP business underperformed expectations." The Company reported revenue for its Design IP segment of \$425.9 million, a 7.7% decline year-over-year and net income of \$242.5 million,



a 43% year-over-year decline. The Company revealed that its Design IP customers require "more and more customization," which "takes longer" and requires "more resources." As a result, the Company stated it was having "an ongoing dialogue with our customers" regarding changing its business model. This news caused the price of Synopsys stock to fall \$217.59 per share, or nearly 36%, from \$604.37 per share on September 9, 2025, to \$387.78 per share on September 10, 2025.

#### What Is the Class Action Deadline?

You may ask the Court no later than December 30, 2025, which is the first business day after 60 days from the date of the publication of notice of pendency of the action, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

#### **Contact Us:**

If you lost money when Synopsys stock dropped in price, you are encouraged to submit your information to speak with an attorney about your rights.

You can also contact: Ross Shikowitz ross@bfalaw.com 212.789.3619

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of the class action lawsuit. The Firm will seek court approval for any potential fees and expenses.

## Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*, and its attorneys have been named "Elite Trial Lawyers" by the *National Law Journal*, among the top "500 Leading Plaintiff Financial Lawyers" by *Lawdragon*, "Titans of the Plaintiffs' Bar" by *Law360* and "SuperLawyers" by Thomson Reuters. Among its recent notable successes, BFA recovered over \$900 million in value from Tesla, Inc.'s Board of Directors, as well as \$420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.